Interagency Patent Coordination and Improvement Act of 2025

HR 4570 establishes an Interagency Task Force on Patents to improve information sharing between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA). The task force will coordinate the sharing of FDA data on drug approvals, labeling, and scientific developments with USPTO patent examiners to help them assess prior art and patent validity for human drugs and biological products. This affects USPTO examiners who review patents and FDA officials who manage drug approval information. The bill requires the USPTO to submit a report within four years evaluating the task force's effectiveness, including which information-sharing methods are most useful and whether coordination with other agencies should expand.